TGF-β and renal fibrosis: a Pandora's box of surprises.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. miR-155-5p Implicates in the Pathogenesis of Renal Fibrosis via Targeting SOCS1 and SOCS6.Oxidative medicine and cellular longevity · 2020
   Article
2. Retracted Article: TMEM88 inhibits fibrosis in renal proximal tubular epithelial cells by suppressing the transforming growth factor-β1/Smad signaling pathway.RSC advances · 2019
   Article
3. Deletion of β1-integrin in collecting duct principal cells leads to tubular injury and renal medullary fibrosis.American journal of physiology. Renal physiology · 2017
   Article
4. Diet-induced increase in plasma oxidized LDL promotes early fibrosis in a renal porcine auto-transplantation model.Journal of translational medicine · 2014
   Article

Corrections and comments

• Comment on
  Lysophosphatidic acid increases proximal tubule cell secretion of profibrotic cytokines PDGF-B and CTGF through LPA2- and Gαq-mediated Rho and αvβ6 integrin-dependent activation of TGF-β.2012

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as